{
  "docId": "019de076-f978-76c3-9c95-6b6ce7102162",
  "docSlug": "c02a1d1cb7557bc430cc8dc61cd27097",
  "documentTitle": "CG Oncology | IPO Presentation Deck | 45 slides",
  "authorId": "cg-oncology",
  "authorName": "CG Oncology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 25,
  "pageCount": 45,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 48,
  "notes": "The slide uses a detailed comparison table to highlight the competitive positioning of CG Oncology's CORE-001 trial against other industry players.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/25",
  "deckHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162",
  "deckJsonHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json",
  "deckAnchorHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.96,
        "x": 0.02,
        "y": 0.93
      },
      "kind": "disclaimer",
      "text": "These data are not based on head-to-head or comparator studies. Differences exist between study designs and subject characteristics...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a0edb97-a68c-4cd5-939e-ec1bd5974299",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.68,
        "w": 0.96,
        "x": 0.02,
        "y": 0.22
      },
      "kind": "table",
      "text": "Comparison table of 8 clinical trials across 10 metrics including Trial, Intervention, Mechanism, RoA, Stage, Sample Size, BCG-Free Regimen, CR Any Time, CR 6 Mo, CR 12 Mo, and Safety Profile.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6726bcd-e7a8-4bed-be18-ca2a70e34674",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.21,
        "y": 0.03
      },
      "kind": "title",
      "text": "Pioneering Oncolytic Immunotherapy with Differentiated Clinical Results Compared to Approved and In Development Agents in BCG-UR NMIBC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c9cad47-fd41-4a93-bad2-debfbca3e69e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "fb19ec5d-ee1d-4501-8f54-a9c4026f47fd",
      "evidence": "table/data: Comparison table of 8 clinical trials across 10 metrics including Trial, Intervention, Mechanism, RoA, Stage, Sample Size, BCG-Free Regimen, CR Any Time, CR 6 Mo, CR 12 Mo, and Safety Profile.",
      "confidence": 0.7
    },
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "1cdea73f-d8fd-43f0-be69-ebad89af9a0a",
      "evidence": "table/data: Comparison table of 8 clinical trials across 10 metrics including Trial, Intervention, Mechanism, RoA, Stage, Sample Size, BCG-Free Regimen, CR Any Time, CR 6 Mo, CR 12 Mo, and Safety Profile.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_table",
      "slug": null,
      "matchId": "6124051b-033a-46a7-ae64-2a7fb05cceba",
      "evidence": "The slide is structured as a comparative matrix of clinical trial data across multiple competitors.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed",
      "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').",
      "position": 0,
      "objective": "What are the consequences of not adopting Cretostimogene?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}